A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
暂无分享,去创建一个
M. Nishimura | H. Dosaka-akita | S. Ogura | T. Kojima | K. Yamazaki | T. Ishida | I. Kinoshita | M. Harada | Y. Fujita | H. Yokouchi | H. Asahina | H. Isobe | N. Sukoh | O. B. O. T. M. Group | Y. Okamoto